NCT04901325View on ClinicalTrials.gov

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 3, 2023

Primary Completion Date

January 5, 2025

Study Completion Date

May 7, 2025

Conditions
Pyoderma GangrenosumSkin DiseasesWound HealPyodermaSkin Ulcer
Interventions
DRUG

Baricitinib

Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Oregon Health and Science University

OTHER

NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Biotech Hunter | Biotech Hunter